Associations of the DRD2 gene polymorphism (rs1800497) with the development of substance use disorders in adolescence Authors
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
The article presents the results of an observational cross-sectional study in the field of adolescent addiction psychiatry. It provides up-to-date information on substance use among adolescents and its association with the DRD2 gene polymorphism (rs1800497), which encodes the type 2 dopamine receptor. The study aimed to investigate the association between this genetic marker and the development of substance use disorders in adolescents. The study included 188 adolescents aged 15 to 18 years. An analysis of genotype and allele frequency distributions was conducted, and the association of the A1 allele carriage with qualitative and quantitative indicators of various classes of substance use, as well as the need for inpatient treatment, was evaluated. The results established that carriers of the A1 allele (A1/A1 and A1/A2 genotypes) were significantly more likely to try and subsequently misuse synthetic cannabinoids, synthetic cathinones, hallucinogens, and volatile organic substances compared to A2/A2 homozygotes. A dose-dependent effect of the A1 allele was identified regarding the use of synthetic cathinones. The presence of at least one A1 allele was associated with higher odds of admission to an addiction treatment hospital. The findings suggest that the A1 allele of the DRD2 gene can be considered a significant risk marker for the development of substance use disorders in adolescents.
Fields of Study & Subjects
Neurotransmitter Receptor Influence on Behavior
Substance Abuse Treatment and Outcomes
Genetic Associations and Epidemiology
Publication details
- Journal / source
- Medicina
- Volume
- 14
- Issue
- 1
- Pages
- 36–49
- Publication date
- 1 January 2026
- Language
- EN